Articles On Respiri (ASX:RSH)

Respiri (RSH) establishes a Philippine-based Company Centre of Digital Innovation Excellence following an internal review of its global growth requirementsThe Centre of Excellence will undertake the design and development of software underp...

ASX 200 down 1.6% Small caps short 1.3% Real Estate stocks hit ahead of FOMC meet   The benchmark killed Tuesday only to find its very own number was up today. The ASX 200 has spent the session retracing yesterday’s 1.3% gains – driven b...

The ASX 200 is vacillating Small caps are down over 1.3% Demetallica is a great name and it’s up 40% on takeover talk   The benchmark ASX 200 is flat as on Monday. The ASX Emerging Companies (XEC) index has lost 1.3%. REITs and Gold are h...

Opyl has a new experienced chairman to lead the company into its next stage of growth on the back of successful FY22 results and its flagship platform ready for international launch. Medtech Opyl (ASX:OPL) has announced the appointment of...

The ASX200 is down 0.24% dragged down by the tech sector Eight out of eleven sectors were lower, with Tech leading the losers CBA says the unemployment rate is at its lowest in 48 years   Despite creeping up earlier in the week the ASX 20...

Respiri gives update on US market Screening results from 19 of Emyria’s MDMA compounds have been returned Telix reports strong half-year results Respiratory disease specialist, Respiri (ASX:RSH), surged 14% this morning after updating the...

HeraMed signs US deal worth $500k Pregnancy medtech specialist, HeraMed (ASX:HMD), was up over 20% this morning after revealing a supply deal with US-based e-Lōvu Health. The expected revenue to HeraMED from the deal is approximately US$550...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

King’s College, London (KCL) receives a National Institute for Health Research (NIHR) funded UK paediatric asthma clinical trial using Respiri’s (RSH) wheezo device The £2 million trial will assess the impact of the device when combined w...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Literally every sector had a red month, but mining was the worst PayGroup gets surprise $120m takeover offer from US unicorn Deel Tempest Minerals signed JV to explore near the Karara Magnetite Iron mine June was a month of global econom...

Tech leads losses on local markets ASX 200 gives away early gains, XEC dives more than 1% again BNPL names big and small get smaller   Small Caps are sharply lower and the ASX 200 is wandering aimlessly on Wednesday as tech names tumble...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Health technology company Respiri (ASX: RSH) has unveiled a $1.5 million capital raising as it fast-tracks its expansion through the US respiratory health market, which is forecast to be worth US$85 billion by 2026. The funds will be used t...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

eHealth company Respiri (RSH) enters a trading halt ahead of a capital raise So far, there is no information on how much the company is aiming to raise or where the funds will be spent Under the halt, company shares will be paused until Fr...

Halo Technologies (HAL) shares have plunged 27.5 per cent since its ASX debut yesterday. The listing came after the company raised more than $36 million through an IPO priced at $1.20 per share. The Australian business offers global s...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Asthma management specialist Respiri (ASX: RSH) has signed a deal with US boutique firm EAS Advisors LLC to accelerate its expansion into the North American market. Respiri, which develops solutions to improve the management of chronic and...

Respiri Limited (RSH) announces its first remote patient monitoring (RPM) pilot program involving its “wheezo” product with the Children’s Hospital of Michigan in the US The program has been secured with Respiri’s RPM partner Access Telehe...

Clinuvel releases positive preliminary results from pilot study Cann’s Mildura cannabis facility is ready Imugene signs deal with Merck Respiri provides wheezo to children’s hospital in Michigan The ASX 200 Health Index (XHJ) is trading l...

Respiratory health management specialist Respiri (ASX: RSH) has launched its first reimbursed remote patient monitoring (RPM) pilot program involving flagship product wheezo at the Children’s Hospital of Michigan. The program was secured wi...

ASX to fall, Nasdaq shaves another 2% Wall Street was mainly lower overnight, as the tech heavy Nasdaq index slipped another 2% following its 2% fall on Friday. The S&P 500 index also closed lower by 0.74%, while the Dow finished flat....

For now, all roads for ASX shares still lead back to the Russia-Ukraine war. And today investors hit the risk-off button as the conflict still looks to be well and truly in the escalation phase. The five-day winning streak for ASX microcaps...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Peter Switzer talks with Respiri (RSH) CEO, Marjan Mikel.

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Respiri (RSH) signs a second, five-year, non-exclusive distribution and marketing agreement with Access Telehealth in the United States Access is a premier provider of Remote Patient Monitoring (RPM) and telehealth services utilising their...

Respiri (RSH) secures a second order for Wheezo from mTelehealth Respiri has teamed up with mTelehealth to provide customers with the Wheezo device for evaluation, testing and pilot programs, which are considered the first steps towards se...

The ASX 200 Health Index (XHJ) and the benchmark ASX 200 are trading flat today. Proteomics advances on blood test results Investors gave Proteomics International Laboratories (ASX:PIQ) the thumbs up after the company said it has identified...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

The Respiri Ltd (ASX: RSH) share price leapt 14% to 6.5 cents in early trading this morning. This came following the announcement of a distribution and marketing deal with a United States healthcare company. At the closing bell, Respiri s...

Respiri (RSH) signs a five-year non-exclusive distribution and marketing deal with US-based remote patient monitoring (RPM) and chronic care provider, mTelehealth mTelehealth will initially order US$150,000 (A$208,087) worth of wheezo devi...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Summary Now Respiri’s Wheezo to be sold across pharmacies in Australia Value rises across DEXUS property portfolio BetMakers purchases assets of Form Cruncher and Swopstakes Adacel wins contract for air traffic management, shares ga...

Summary The ASX 200 ended lower by 43.70 points or 0.60% at 7,298.50, led by losses in health care, energy, and banking stock. All sectoral indices, barring tech and materials, ended in red. The market sentiment was dented by concerns...

23 Jun 2021 - A snapshot of notable stock news for the hour, featuring ikeGPS Group, Wide Open Agriculture, Respiri & NeuroScientific Biopharmaceuticals.

23 Jun 2021 - Respiri (ASX:RSH) has announced the commencement of sales of its wheezo asthma-management product across over 570 pharmacies within the Sigma Healthcare (ASX:SIG) net…

The Respiri Ltd (ASX: RSH) share price is racing higher today after the company announced the addition of another pharmacy network for the sale of its wheezo product. Upon the commencement of trade this morning, shares in Respiri increased...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Wall Street rebounds as Nasdaq resets record high All three major US benchmarks rose overnight, as investors adjusted to the Fed’s rate outlook. The Dow Jones rose by 0.20%, S&P 500 by 0.51%, and tech heavy Nasdaq by 0.79%. Nasdaq close...

Fertoz Ltd (ASX:FTZ) topped the pops with a red hot 14-day RSI of 93 after two massive days to finish the week. A total of 18 ASX companies posted a 14-day RSI above 70 last week, down from 25 in the week prior. Each week, Stockhead recaps...